{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-10",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "submissions": [
        {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20240426",
          "review_priority": "PRIORITY",
          "submission_class_code": "TYPE 1",
          "submission_class_code_description": "Type 1 - New Molecular Entity",
          "submission_property_type": [
            {
              "code": "Orphan"
            }
          ],
          "application_docs": [
            {
              "id": "78285",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf",
              "date": "20240429",
              "type": "Label"
            },
            {
              "id": "78301",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218709Orig1s000ltr.pdf",
              "date": "20240429",
              "type": "Letter"
            },
            {
              "id": "78566",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218709Orig1s000TOC.html",
              "date": "20240528",
              "type": "Review"
            }
          ]
        }
      ],
      "application_number": "NDA218709",
      "sponsor_name": "X4 PHARMS",
      "openfda": {
        "application_number": [
          "NDA218709"
        ],
        "brand_name": [
          "XOLREMDI"
        ],
        "generic_name": [
          "MAVORIXAFOR"
        ],
        "manufacturer_name": [
          "X4 Pharmaceuticals, Inc."
        ],
        "product_ndc": [
          "83296-100"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "MAVORIXAFOR"
        ],
        "rxcui": [
          "2684026",
          "2684032"
        ],
        "spl_id": [
          "26bdd232-8068-9080-e063-6394a90aa084"
        ],
        "spl_set_id": [
          "7f3a5ee3-ca73-4876-85a0-ed1e108a2237"
        ],
        "package_ndc": [
          "83296-100-60",
          "83296-100-90",
          "83296-100-12"
        ],
        "nui": [
          "N0000194104",
          "N0000194105",
          "N0000182137",
          "N0000182141",
          "N0000185503"
        ],
        "pharm_class_epc": [
          "CXC Chemokine Receptor 4 Antagonist [EPC]"
        ],
        "pharm_class_moa": [
          "CXC Chemokine Receptor 4 Antagonists [MoA]",
          "Cytochrome P450 2D6 Inhibitors [MoA]",
          "Cytochrome P450 3A4 Inhibitors [MoA]",
          "P-Glycoprotein Inhibitors [MoA]"
        ],
        "unii": [
          "0G9LGB5O2W"
        ]
      },
      "products": [
        {
          "product_number": "001",
          "reference_drug": "Yes",
          "brand_name": "XOLREMDI",
          "active_ingredients": [
            {
              "name": "MAVORIXAFOR",
              "strength": "100MG"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "CAPSULE",
          "route": "ORAL",
          "marketing_status": "Prescription"
        }
      ]
    }
  ]
}